Screener
Dogwood Therapeutics DWTX Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Dogwood Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Dogwood Therapeutics’s 10-Q, filed May 15, 2026.
- Filed
- May 15, 2026, 9:20 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-061938
| Revenue | Three Months Ended / March 31, 2026 / — | Three Months Ended / March 31, 2025 / — |
|---|---|---|
| Total other income (expense) | 90,945 | (6,304,484) |
| Loss before income taxes | (4,985,421) | (10,734,410) |
| Deferred income tax expense | (1,193) | (190,542) |
| Net loss | (4,986,614) | (10,924,952) |
| Accrual of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock | — | (1,256,662) |
| Net loss attributable to common stockholders | $(4,986,614) | $(12,181,614) |
| Net loss per common share, basic and diluted | $(0.15) | $(8.45) |
| Weighted average number of shares outstanding – basic and diluted | 33,544,748 | 1,441,535 |
Item 1. Condensed Consolidated Financial Statements
FAQ
- What is Dogwood Therapeutics's net income?
- Dogwood Therapeutics (DWTX) reported net income of -$4.99M in Q1 2026.
- How has Dogwood Therapeutics's net income changed year-over-year?
- Dogwood Therapeutics's net income increased by 54.4% year-over-year, from -$10.92M to -$4.99M.
- What is the long-term trend for Dogwood Therapeutics's net income?
- Over 4 years (2021 to 2025), Dogwood Therapeutics's net income has grown at a 21.0% compound annual growth rate (CAGR), from -$15.96M to -$34.26M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Dogwood Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude